Details

Autor(en) / Beteiligte

• Jensen-Jarolim, Erika, MD
• Turner, Michelle C., PhD
• Karagiannis, Sophia N., PhD

Titel

AllergoOncology: IgE- and IgG4 -mediated immune mechanisms linking allergy with cancer and their translational implications

Ist Teil von

• Journal of allergy and clinical immunology, 2017-10, Vol.140 (4), p.982-984

Ort / Verlag

St. Louis: Elsevier Inc

Erscheinungsjahr

2017

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Since the detection of specific IgE in allergy, its potential role in cancer has been investigated and prompted the definition of the field of AllergoOncology.1 Most recent developments are collected in a position paper by the European Academy of Allergy and Clinical Immunology.2 IgE and cancer IgE is an antibody with properties distinct from those of other isotypes, specifically in terms of its affinity for its cognate Fc receptor Fc[epsilon]RI. IgE is cross-linked by densely packed tumor antigens but not by soluble monovalent antigens, forming tumor-associated molecular patterns (TAMPs) on a cancer cell surface and therefore triggering effector cell activation at sites where antitumor immunity is needed (Fig 1). [...]it is tempting to speculate that IgE antibodies directed against tumor antigens can propagate alternative or complementary antitumor functions to those of clinically available IgG mAbs specific for tumor antigens, such as epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2). From TH2 immune responses in patients with allergy and atopy to cancer epidemiology Allergy is characterized by TH2-dominant immune responses, featuring IL-4, IL-13, and thymic stromal lymphopoietin upregulation. Because these mediators can be observed in cancer tissues, strategies to activate these responses could in principle promote isotype switching to antitumor IgE and also IgE/Fc[epsilon]RI-associated cross-presentation by dendritic cells, resulting in activation of CD4+ T cells but also of CD8+ cytotoxic T lymphocytes. [...]although TH1 responses and a strong branch of CD8+ cytotoxic T lymphocytes are generally desired in oncology, activation of classical TH2 cells has also been associated with improved survival.